SlideShare a Scribd company logo

INDs: When Required and Contents

•
•
L
Louise666

An introduction intended for professionals who are not familiar with Investigational New Drug applications.

1 of 58
Louise Johnson, M.S. INVESTIGATIONAL NEW DRUG APPLICATION (IND) Requirements for Filing and Contents of Submission The Bio2Device Group May 18, 2010
What is an IND, its benefits, & your responsibilities as a sponsor? ,[object Object],[object Object],[object Object]
When an IND is Required ,[object Object],[object Object],[object Object],[object Object]
When an IND is Not Required ,[object Object],[object Object],[object Object]
Examples ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pharmaceutical-Specific Terminology ,[object Object],[object Object],[object Object]
Pharmaceutical-Specific Terminology ,[object Object],[object Object]
Pharmaceutical-Specific Terminology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pharmaceutical-Specific Terminology ,[object Object],[object Object],[object Object],[object Object],[object Object]
Pharmaceutical-Specific Terminology ,[object Object],[object Object],[object Object],[object Object]
Pharmaceutical-Specific Terminology ,[object Object],[object Object],[object Object],[object Object]
Pharmaceutical-Specific Terminology ,[object Object],[object Object],[object Object],[object Object],[object Object]
Pharmaceutical-Specific Terminology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pharmaceutical-Specific Terminology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Typical Development Timeline ,[object Object]
An IND Supports 3 Phases of Clinical Development ,[object Object],[object Object],[object Object]
Phase 1 ,[object Object],[object Object],[object Object],[object Object]
Phase 1 (continued) ,[object Object],[object Object],[object Object]
Phase 2 ,[object Object],[object Object],[object Object]
Phase 3 ,[object Object],[object Object],[object Object],[object Object],[object Object]
IND Regulations and Guidance ,[object Object],[object Object],[object Object],[object Object],[object Object]
IND Content ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
IND Content (continued) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Individual IND Sections
Cover Sheet - Form 1571 ,[object Object],[object Object],[object Object],[object Object]
Cover Sheet - Form 1571 (Cont.) ,[object Object],[object Object],[object Object],[object Object]
IND Table of Contents ,[object Object],[object Object],[object Object]
Introductory Statement and General Investigational Plan (1) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Introductory Statement and General Investigational Plan (2) ,[object Object],[object Object]
Introductory Statement and General Investigational Plan (3) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Investigator’s Brochure ,[object Object],[object Object],[object Object]
Investigator’s Brochure ,[object Object],[object Object],[object Object]
Clinical Protocols ,[object Object],[object Object],[object Object],[object Object]
Clinical Protocols (continued) ,[object Object],[object Object],[object Object]
Clinical Protocols (Continued) ,[object Object],[object Object],[object Object]
Clinical Investigator Information ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Form FDA 1572 ,[object Object],[object Object],[object Object]
Chemistry, Manufacturing, and Control (CMC) ,[object Object],[object Object],[object Object]
CMC (Continued) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CMC (Continued) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CMC (Continued) ,[object Object],[object Object],[object Object]
CMC (Continued) ,[object Object],[object Object]
Nonclinical Information ,[object Object]
Nonclinical Information (continued) ,[object Object],[object Object],[object Object]
Toxicology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Toxicology (continued) ,[object Object],[object Object]
Previous Human Experience ,[object Object],[object Object],[object Object]
Additional Information ,[object Object],[object Object],[object Object],[object Object]
Additional Information ,[object Object],[object Object],[object Object]
Other Considerations ,[object Object],[object Object],[object Object],[object Object]
Other Considerations (Continued) ,[object Object],[object Object],[object Object],[object Object],[object Object]
FDA Review of an IND ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
FDA Review of an IND (continued) ,[object Object],[object Object],[object Object],[object Object]
FDA Review of an IND (continued) ,[object Object],[object Object],[object Object],[object Object],[object Object]
Clinical Hold ,[object Object],[object Object],[object Object]
IND Success ,[object Object]
Useful URLs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Thank you!

Recommended

Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillanceDr. Vijesha Soni
 
Regulation in clinical trial, Schedule Y and recent amendments
Regulation in clinical trial, Schedule Y and recent amendmentsRegulation in clinical trial, Schedule Y and recent amendments
Regulation in clinical trial, Schedule Y and recent amendmentsDr. Siddhartha Dutta
 
IND Application WJ 10Aug14 Final
IND Application WJ 10Aug14 FinalIND Application WJ 10Aug14 Final
IND Application WJ 10Aug14 FinalWilliam Jackson, PharmD, RPh
 
Investigator brochure
Investigator brochureInvestigator brochure
Investigator brochurekanchangupta66
 
Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Sagar Savale
 
schedule y
schedule yschedule y
schedule yRohit K.
 
Marketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureMarketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureOffice of Health Economics
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Aakashdeep Raval
 

Recommended

Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillanceDr. Vijesha Soni
 
Regulation in clinical trial, Schedule Y and recent amendments
Regulation in clinical trial, Schedule Y and recent amendmentsRegulation in clinical trial, Schedule Y and recent amendments
Regulation in clinical trial, Schedule Y and recent amendmentsDr. Siddhartha Dutta
 
IND Application WJ 10Aug14 Final
IND Application WJ 10Aug14 FinalIND Application WJ 10Aug14 Final
IND Application WJ 10Aug14 FinalWilliam Jackson, PharmD, RPh
 
Investigator brochure
Investigator brochureInvestigator brochure
Investigator brochurekanchangupta66
 
Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Sagar Savale
 
schedule y
schedule yschedule y
schedule yRohit K.
 
Marketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureMarketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureOffice of Health Economics
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Aakashdeep Raval
 
Schedule y
Schedule ySchedule y
Schedule ykumargourav40
 
Site & investigator selection
Site & investigator selectionSite & investigator selection
Site & investigator selectionMukesh Jaiswal
 
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)ClinosolIndia
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYdatchayani
 
21 cfr part 50
21 cfr part 5021 cfr part 50
21 cfr part 50Rohit K.
 
Investigational new drug application (ind)
Investigational new drug application (ind)Investigational new drug application (ind)
Investigational new drug application (ind)Siddu K M
 
Anda review process
Anda review processAnda review process
Anda review processbinnz
 
Choice of control group in clinical trials
Choice of control group in clinical trialsChoice of control group in clinical trials
Choice of control group in clinical trialsNagendra SR
 
Investigator's Brochure
Investigator's BrochureInvestigator's Brochure
Investigator's BrochureRiyaz Gohil
 
Guidance for industry content and format of investigational new drug applicat...
Guidance for industry content and format of investigational new drug applicat...Guidance for industry content and format of investigational new drug applicat...
Guidance for industry content and format of investigational new drug applicat...Suraj Pamadi
 
ind
indind
indRohit K.
 
Ethical committee-role, Principal Investigator
Ethical committee-role, Principal InvestigatorEthical committee-role, Principal Investigator
Ethical committee-role, Principal InvestigatorGayathri Ravi
 
Drug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuDrug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuAngelinabarfield
 
INVESTIGATOR’S BROCHURE (IB)
INVESTIGATOR’S BROCHURE (IB) INVESTIGATOR’S BROCHURE (IB)
INVESTIGATOR’S BROCHURE (IB)SachinFartade
 
Regulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USARegulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USAsandeep bansal
 
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)Swapnil Fernandes
 
Clinical Research Regulation in European Union
Clinical Research Regulation in European Union Clinical Research Regulation in European Union
Clinical Research Regulation in European Union ShantanuThakre3
 
Cdsco ppt
Cdsco pptCdsco ppt
Cdsco pptNikhat Sheikh
 
Comparasion of IND,NDA,BLA,ANDA,OTC
Comparasion of IND,NDA,BLA,ANDA,OTCComparasion of IND,NDA,BLA,ANDA,OTC
Comparasion of IND,NDA,BLA,ANDA,OTCGuru Balaji .S
 
ANDA
ANDAANDA
ANDASagar Savale
 
Good manufacturing practice (GMP)
Good manufacturing practice (GMP)Good manufacturing practice (GMP)
Good manufacturing practice (GMP)Sagar Savale
 
Quality Management Systems
Quality Management SystemsQuality Management Systems
Quality Management SystemsThe Bulgarian Association of Regional Development Agencies (BARDA)
 

More Related Content

What's hot

Site & investigator selection
Site & investigator selectionSite & investigator selection
Site & investigator selectionMukesh Jaiswal
 
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)ClinosolIndia
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYdatchayani
 
21 cfr part 50
21 cfr part 5021 cfr part 50
21 cfr part 50Rohit K.
 
Investigational new drug application (ind)
Investigational new drug application (ind)Investigational new drug application (ind)
Investigational new drug application (ind)Siddu K M
 
Anda review process
Anda review processAnda review process
Anda review processbinnz
 
Choice of control group in clinical trials
Choice of control group in clinical trialsChoice of control group in clinical trials
Choice of control group in clinical trialsNagendra SR
 
Investigator's Brochure
Investigator's BrochureInvestigator's Brochure
Investigator's BrochureRiyaz Gohil
 
Guidance for industry content and format of investigational new drug applicat...
Guidance for industry content and format of investigational new drug applicat...Guidance for industry content and format of investigational new drug applicat...
Guidance for industry content and format of investigational new drug applicat...Suraj Pamadi
 
Ethical committee-role, Principal Investigator
Ethical committee-role, Principal InvestigatorEthical committee-role, Principal Investigator
Ethical committee-role, Principal InvestigatorGayathri Ravi
 
Drug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuDrug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuAngelinabarfield
 
INVESTIGATOR’S BROCHURE (IB)
INVESTIGATOR’S BROCHURE (IB) INVESTIGATOR’S BROCHURE (IB)
INVESTIGATOR’S BROCHURE (IB)SachinFartade
 
Regulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USARegulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USAsandeep bansal
 
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)Swapnil Fernandes
 
Clinical Research Regulation in European Union
Clinical Research Regulation in European Union Clinical Research Regulation in European Union
Clinical Research Regulation in European Union ShantanuThakre3
 
Comparasion of IND,NDA,BLA,ANDA,OTC
Comparasion of IND,NDA,BLA,ANDA,OTCComparasion of IND,NDA,BLA,ANDA,OTC
Comparasion of IND,NDA,BLA,ANDA,OTCGuru Balaji .S
 

What's hot (20)

Schedule y
Schedule ySchedule y
Schedule y
 
Site & investigator selection
Site & investigator selectionSite & investigator selection
Site & investigator selection
 
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCY
 
21 cfr part 50
21 cfr part 5021 cfr part 50
21 cfr part 50
 
Investigational new drug application (ind)
Investigational new drug application (ind)Investigational new drug application (ind)
Investigational new drug application (ind)
 
Anda review process
Anda review processAnda review process
Anda review process
 
Choice of control group in clinical trials
Choice of control group in clinical trialsChoice of control group in clinical trials
Choice of control group in clinical trials
 
Investigator's Brochure
Investigator's BrochureInvestigator's Brochure
Investigator's Brochure
 
Guidance for industry content and format of investigational new drug applicat...
Guidance for industry content and format of investigational new drug applicat...Guidance for industry content and format of investigational new drug applicat...
Guidance for industry content and format of investigational new drug applicat...
 
ind
indind
ind
 
Ethical committee-role, Principal Investigator
Ethical committee-role, Principal InvestigatorEthical committee-role, Principal Investigator
Ethical committee-role, Principal Investigator
 
Drug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuDrug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And Eu
 
INVESTIGATOR’S BROCHURE (IB)
INVESTIGATOR’S BROCHURE (IB) INVESTIGATOR’S BROCHURE (IB)
INVESTIGATOR’S BROCHURE (IB)
 
Regulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USARegulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USA
 
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)
 
Clinical Research Regulation in European Union
Clinical Research Regulation in European Union Clinical Research Regulation in European Union
Clinical Research Regulation in European Union
 
Cdsco ppt
Cdsco pptCdsco ppt
Cdsco ppt
 
Comparasion of IND,NDA,BLA,ANDA,OTC
Comparasion of IND,NDA,BLA,ANDA,OTCComparasion of IND,NDA,BLA,ANDA,OTC
Comparasion of IND,NDA,BLA,ANDA,OTC
 
ANDA
ANDAANDA
ANDA
 

Viewers also liked

Good manufacturing practice (GMP)
Good manufacturing practice (GMP)Good manufacturing practice (GMP)
Good manufacturing practice (GMP)Sagar Savale
 
IND Application Process and Best Practices
IND Application Process and Best PracticesIND Application Process and Best Practices
IND Application Process and Best PracticesCFTCC
 
Quality Management Systems Potential LLC Brochure
Quality Management Systems Potential LLC BrochureQuality Management Systems Potential LLC Brochure
Quality Management Systems Potential LLC BrochureSteve Gompertz
 
Quality & compliance excellence in pharmaceuticals
Quality & compliance excellence in pharmaceuticalsQuality & compliance excellence in pharmaceuticals
Quality & compliance excellence in pharmaceuticalsAnvita Bharati
 
Reg & Qa GMP
Reg & Qa GMPReg & Qa GMP
Reg & Qa GMPLouise666
 
Quality management systems for medical, pharmaceutical,
Quality management systems for medical, pharmaceutical,Quality management systems for medical, pharmaceutical,
Quality management systems for medical, pharmaceutical,Khalizan Halid
 
Quality Management System of Coca-Cola
Quality Management System of Coca-ColaQuality Management System of Coca-Cola
Quality Management System of Coca-ColaTharushika Ruwangi
 
Quality Management Systems in different industries - from ISO 9001 to cGxP
Quality Management Systems in different industries - from ISO 9001 to cGxPQuality Management Systems in different industries - from ISO 9001 to cGxP
Quality Management Systems in different industries - from ISO 9001 to cGxPPauwels Consulting
 
Total quality management 1 .pps
Total quality management 1 .ppsTotal quality management 1 .pps
Total quality management 1 .ppsharshavardhanan
 
Total quality management (tqm)ادارة الجودة الشاملة
Total quality management (tqm)ادارة الجودة الشاملةTotal quality management (tqm)ادارة الجودة الشاملة
Total quality management (tqm)ادارة الجودة الشاملةIbrahim Alhariri
 

Viewers also liked (13)

Good manufacturing practice (GMP)
Good manufacturing practice (GMP)Good manufacturing practice (GMP)
Good manufacturing practice (GMP)
 
Quality Management Systems
Quality Management SystemsQuality Management Systems
Quality Management Systems
 
IND Application Process and Best Practices
IND Application Process and Best PracticesIND Application Process and Best Practices
IND Application Process and Best Practices
 
Supplier Selection
Supplier SelectionSupplier Selection
Supplier Selection
 
Quality Management Systems Potential LLC Brochure
Quality Management Systems Potential LLC BrochureQuality Management Systems Potential LLC Brochure
Quality Management Systems Potential LLC Brochure
 
Quality & compliance excellence in pharmaceuticals
Quality & compliance excellence in pharmaceuticalsQuality & compliance excellence in pharmaceuticals
Quality & compliance excellence in pharmaceuticals
 
Reg & Qa GMP
Reg & Qa GMPReg & Qa GMP
Reg & Qa GMP
 
Quality management systems for medical, pharmaceutical,
Quality management systems for medical, pharmaceutical,Quality management systems for medical, pharmaceutical,
Quality management systems for medical, pharmaceutical,
 
Quality Management System of Coca-Cola
Quality Management System of Coca-ColaQuality Management System of Coca-Cola
Quality Management System of Coca-Cola
 
Quality Management Systems in different industries - from ISO 9001 to cGxP
Quality Management Systems in different industries - from ISO 9001 to cGxPQuality Management Systems in different industries - from ISO 9001 to cGxP
Quality Management Systems in different industries - from ISO 9001 to cGxP
 
Total quality management 1 .pps
Total quality management 1 .ppsTotal quality management 1 .pps
Total quality management 1 .pps
 
QUALITY ASSURANCE
QUALITY ASSURANCEQUALITY ASSURANCE
QUALITY ASSURANCE
 
Total quality management (tqm)ادارة الجودة الشاملة
Total quality management (tqm)ادارة الجودة الشاملةTotal quality management (tqm)ادارة الجودة الشاملة
Total quality management (tqm)ادارة الجودة الشاملة
 

Similar to INDs: When Required and Contents

PART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptxPART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptxDilsarGohil1
 
Worldwide comprehensive study of guideline on clinical trial
Worldwide comprehensive study of guideline on clinical trialWorldwide comprehensive study of guideline on clinical trial
Worldwide comprehensive study of guideline on clinical trialRGPV BHOPAL
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)Saiyad Arsh zia
 
Overview regulatory environment in usa,europe,india
Overview regulatory environment in usa,europe,indiaOverview regulatory environment in usa,europe,india
Overview regulatory environment in usa,europe,indiashabana parveen
 
INVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONINVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONKomal Yadav
 
INDA- Investigation New Drug Application
INDA- Investigation New Drug ApplicationINDA- Investigation New Drug Application
INDA- Investigation New Drug ApplicationDr. Jigar Vyas
 
Regulatory affairs.pptx
Regulatory affairs.pptxRegulatory affairs.pptx
Regulatory affairs.pptxSrijitaDhara
 
Regulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy IIRegulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy IIJafarali Masi
 
Regulatory requirements for drug approval
Regulatory requirements for drug approval Regulatory requirements for drug approval
Regulatory requirements for drug approval Namdeo Shinde
 
Non-clinical drug development
Non-clinical drug developmentNon-clinical drug development
Non-clinical drug developmentJayeshRajput7
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...Audumbar Mali
 
IND Data Requirements and US FDA Submission.pdf
IND Data Requirements and US FDA Submission.pdfIND Data Requirements and US FDA Submission.pdf
IND Data Requirements and US FDA Submission.pdfProRelix Research
 
Investigational new drug application new
Investigational new drug application newInvestigational new drug application new
Investigational new drug application newAakrati Gupta
 
INVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONINVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONBindu Kshtriya
 

Similar to INDs: When Required and Contents (20)

PART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptxPART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptx
 
Worldwide comprehensive study of guideline on clinical trial
Worldwide comprehensive study of guideline on clinical trialWorldwide comprehensive study of guideline on clinical trial
Worldwide comprehensive study of guideline on clinical trial
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)
 
Overview regulatory environment in usa,europe,india
Overview regulatory environment in usa,europe,indiaOverview regulatory environment in usa,europe,india
Overview regulatory environment in usa,europe,india
 
INVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONINVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATION
 
INDA- Investigation New Drug Application
INDA- Investigation New Drug ApplicationINDA- Investigation New Drug Application
INDA- Investigation New Drug Application
 
Regulatory affairs.pptx
Regulatory affairs.pptxRegulatory affairs.pptx
Regulatory affairs.pptx
 
Regulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy IIRegulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy II
 
CLINICAL TRIALS.pptx
CLINICAL TRIALS.pptxCLINICAL TRIALS.pptx
CLINICAL TRIALS.pptx
 
Regulatory requirements for drug approval
Regulatory requirements for drug approval Regulatory requirements for drug approval
Regulatory requirements for drug approval
 
NDA ANDA IND by Anthony Crasto
NDA ANDA IND by Anthony CrastoNDA ANDA IND by Anthony Crasto
NDA ANDA IND by Anthony Crasto
 
Non-clinical drug development
Non-clinical drug developmentNon-clinical drug development
Non-clinical drug development
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
 
Unit2 clinical trials
Unit2 clinical trialsUnit2 clinical trials
Unit2 clinical trials
 
IND Data Requirements and US FDA Submission.pdf
IND Data Requirements and US FDA Submission.pdfIND Data Requirements and US FDA Submission.pdf
IND Data Requirements and US FDA Submission.pdf
 
Indstudies
Indstudies Indstudies
Indstudies
 
Ind 30
Ind 30Ind 30
Ind 30
 
Development of drug
Development of drugDevelopment of drug
Development of drug
 
Investigational new drug application new
Investigational new drug application newInvestigational new drug application new
Investigational new drug application new
 
INVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONINVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATION
 

INDs: When Required and Contents

  • 1. Louise Johnson, M.S. INVESTIGATIONAL NEW DRUG APPLICATION (IND) Requirements for Filing and Contents of Submission The Bio2Device Group May 18, 2010
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50.
  • 51.
  • 52.
  • 53.
  • 54.
  • 55.
  • 56.
  • 57.
  • 58.